EPIQ Capital Group LLC Sells 49,979 Shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH)

EPIQ Capital Group LLC lessened its stake in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) by 6.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 689,447 shares of the company’s stock after selling 49,979 shares during the period. EPIQ Capital Group LLC owned approximately 2.40% of Cyclo Therapeutics worth $407,000 at the end of the most recent reporting period.

Cyclo Therapeutics Stock Performance

Shares of Cyclo Therapeutics stock opened at $0.74 on Monday. The company has a 50-day simple moving average of $0.79 and a two-hundred day simple moving average of $0.73. The stock has a market capitalization of $24.23 million, a PE ratio of -0.82 and a beta of -0.57. Cyclo Therapeutics, Inc. has a 52-week low of $0.55 and a 52-week high of $1.79.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.